PubMed=7695406; DOI=10.1016/0003-4975(95)00045-M
Pass H.I., Stevens E.J., Oie H.K., Tsokos M.G., Abati A.D., Fetsch P.A., Mew D.J.Y., Pogrebniak H.W., Matthews W.J.
Characteristics of nine newly derived mesothelioma cell lines.
Ann. Thorac. Surg. 59:835-844(1995)

PubMed=8806092; DOI=10.1002/jcb.240630505
Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.
NCI-Navy Medical Oncology Branch cell line data base.
J. Cell. Biochem. 63 Suppl. 24:32-91(1996)

PubMed=11030152; DOI=10.1038/sj.onc.1203815
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Oncogene 19:4632-4639(2000)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164
Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T., Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H., Sekido Y.
LATS2 is a tumor suppressor gene of malignant mesothelioma.
Cancer Res. 71:873-883(2011)

PubMed=21642991; DOI=10.1038/ng.855
Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Nat. Genet. 43:668-672(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24926545; DOI=10.1097/JTO.0000000000000202
Riquelme E., Suraokar M.B., Rodriguez J., Mino B., Lin H.Y., Rice D.C., Tsao A., Wistuba I.I.
Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
J. Thorac. Oncol. 9:998-1007(2014)